Updated January 24, 2020
A new FDA-approved drug that provides fast-acting insulin to children with Type 1 diabetes was developed thanks to contributions from researchers with UB, UBMD and Oishei Children’s Hospital. “Part of the reason this drug was developed was to have a better timeline of action that’s closer to natural insulin,” said Lucy D. Mastrandrea, MD, PhD, associate professor of pediatrics and chief of the Division of Endocrinology/Diabetes. The stories also quote Kathleen E. Bethin, MD, PhD, clinical professor of pediatrics.
